Falch, Camilla M. http://orcid.org/0000-0001-9894-5245
Dupont, Anne K.
Olarescu, Nicoleta C.
Wiedmann, Markus
Dahlberg, Daniel
Bollerslev, Jens
Berg-Johnsen, Jon
Heck, Ansgar
Funding for this research was provided by:
University of Oslo
Article History
Received: 20 April 2023
Accepted: 17 August 2023
First Online: 4 September 2023
Declarations
:
: The study was approved by the hospital authority (no 22/17167).
: As the study was a registry-based quality control study based on clinical data, the requirement to obtain any informed consent was waived by the Regional Ethical Committee of the South-Eastern Health Region of Norway (REK).
: Camilla M. Falch received lecture fees from Pfizer. Nicoleta C. Olarescu received lecture fees from CORE2ED (supported by a medical education grant from Ipsen) and Pfizer. Jens Bollerslev received lecture fees from Ipsen and Pfizer, and served as an advisory board member for Pfizer. Ansgar Heck received lecture fees from Recordati and Ipsen. Anne K. Dupont, Markus Wiedmann, Daniel Dahlberg, and Jon Berg-Johnsen have nothing to declare.